Found: 86
Select item for more details and to access through your institution.
Infectious and immunological sequelae of daratumumab in multiple myeloma.
- Published in:
- Angewandte Chemie, 2019, v. 131, n. 15, p. 187, doi. 10.1111/bjh.15433
- By:
- Publication type:
- Article
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 4, p. 523, doi. 10.1002/ajh.27207
- By:
- Publication type:
- Article
Siltuximab administration results in spurious IL‐6 elevation in peripheral blood.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 1, p. E15, doi. 10.1002/ajh.27132
- By:
- Publication type:
- Article
Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 11, p. E334, doi. 10.1002/ajh.27065
- By:
- Publication type:
- Article
First‐ versus second‐generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta‐analysis.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 7, p. 942, doi. 10.1002/ajh.26552
- By:
- Publication type:
- Article
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 6, p. E195, doi. 10.1002/ajh.26530
- By:
- Publication type:
- Article
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. 1241, doi. 10.1002/ajh.26292
- By:
- Publication type:
- Article
Persistent bone marrow minimal residual disease as a "high‐risk" disease feature in multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. E341, doi. 10.1002/ajh.26255
- By:
- Publication type:
- Article
Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease.
- Published in:
- American Journal of Hematology, 2018, v. 93, n. 7, p. 902, doi. 10.1002/ajh.25123
- By:
- Publication type:
- Article
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 8, p. 739, doi. 10.1002/ajh.24756
- By:
- Publication type:
- Article
Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.919489
- By:
- Publication type:
- Article
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 2, p. 190, doi. 10.1111/ejh.14214
- By:
- Publication type:
- Article
Combinatorial treatment for unresectable unicentric Castleman disease.
- Published in:
- European Journal of Haematology, 2021, v. 107, n. 4, p. 484, doi. 10.1111/ejh.13685
- By:
- Publication type:
- Article
Monitoring treatment response and disease progression in myeloma with circulating cell‐free DNA.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 2, p. 230, doi. 10.1111/ejh.13541
- By:
- Publication type:
- Article
Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
- Published in:
- Journal of Bone & Mineral Research, 2017, v. 32, n. 6, p. 1261, doi. 10.1002/jbmr.3111
- By:
- Publication type:
- Article
Superior 12-Year Survival After at Least 4-Year Continuous Remission with Tandem Transplantations for Multiple Myeloma.
- Published in:
- Clinical Lymphoma & Myeloma, 2006, v. 6, n. 6, p. 469
- By:
- Publication type:
- Article
3195 Genomic Analysis of Primary Plasma Cell Leukemia reveals Complex Cytogenetic Alterations and High Risk Mutational Patterns.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
- Published in:
- Diagnostic Pathology, 2018, v. 13, p. 1, doi. 10.1186/s13000-018-0692-1
- By:
- Publication type:
- Article
Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 24, p. 16170, doi. 10.3390/ijms232416170
- By:
- Publication type:
- Article
Ehrlichia‐induced hemophagocytic lymphohistiocytosis after autologous stem cell transplant.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 3, p. e171, doi. 10.1016/j.clml.2022.12.003
- By:
- Publication type:
- Article
Circulating cell free DNA is a biomarker for GEP70 risk score and tumor burden in myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e62, doi. 10.1016/j.clml.2019.09.096
- By:
- Publication type:
- Article
Long-term Analysis Of Multiple Sequential Samples Reveals Patterns Of Progression In Smoldering Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e59, doi. 10.1016/j.clml.2019.09.092
- By:
- Publication type:
- Article
A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e4, doi. 10.1016/j.clml.2019.09.006
- By:
- Publication type:
- Article
Atrial Fibrillation in Hematologic Malignancies, Especially After Autologous Hematopoietic Stem Cell Transplantation: Review of Risk Factors, Current Management, and Future Directions.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Eruptive Cherry Hemangiomatosis Associated With Multicentric Castleman Disease.
- Published in:
- JAMA Dermatology, 2013, v. 149, n. 2, p. 204, doi. 10.1001/jamadermatol.2013.1552
- By:
- Publication type:
- Article
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01003-z
- By:
- Publication type:
- Article
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00998-9
- By:
- Publication type:
- Article
Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
- Published in:
- Blood Cancer Journal, 2020, v. 10, n. 6, p. 1, doi. 10.1038/s41408-020-0336-z
- By:
- Publication type:
- Article
An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 8, p. N.PAG, doi. 10.1038/s41408-019-0226-4
- By:
- Publication type:
- Article
A gene signature can predict risk of MGUS progressing to multiple myeloma.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01472-y
- By:
- Publication type:
- Article
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients.
- Published in:
- British Journal of Haematology, 2010, v. 150, n. 5, p. 554, doi. 10.1111/j.1365-2141.2010.08286.x
- By:
- Publication type:
- Article
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3.
- Published in:
- British Journal of Haematology, 2009, v. 147, n. 3, p. 347, doi. 10.1111/j.1365-2141.2009.07864.x
- By:
- Publication type:
- Article
Cytogenetic abnormalities in multiple myeloma: poor prognosis linked to concomitant detection in random and focal lesion bone marrow samples and associated with high-risk gene expression profile.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 5, p. 637, doi. 10.1111/j.1365-2141.2009.07670.x
- By:
- Publication type:
- Article
Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation.
- Published in:
- British Journal of Haematology, 2008, v. 143, n. 5, p. 641, doi. 10.1111/j.1365-2141.2008.07340.x
- By:
- Publication type:
- Article
Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.
- Published in:
- British Journal of Haematology, 2008, v. 141, n. 4, p. 433, doi. 10.1111/j.1365-2141.2008.06982.x
- By:
- Publication type:
- Article
Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.
- Published in:
- British Journal of Haematology, 2008, v. 140, n. 6, p. 625, doi. 10.1111/j.1365-2141.2007.06921.x
- By:
- Publication type:
- Article
Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
- Published in:
- British Journal of Haematology, 2007, v. 138, n. 2, p. 176, doi. 10.1111/j.1365-2141.2007.06639.x
- By:
- Publication type:
- Article
Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.
- Published in:
- British Journal of Haematology, 2007, v. 137, n. 6, p. 530, doi. 10.1111/j.1365-2141.2007.06586.x
- By:
- Publication type:
- Article
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
- Published in:
- British Journal of Haematology, 2007, v. 136, n. 3, p. 393, doi. 10.1111/j.1365-2141.2006.06441.x
- By:
- Publication type:
- Article
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.
- Published in:
- British Journal of Haematology, 2006, v. 135, n. 2, p. 158, doi. 10.1111/j.1365-2141.2006.06271.x
- By:
- Publication type:
- Article
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
- Published in:
- British Journal of Haematology, 2004, v. 126, n. 5, p. 715, doi. 10.1111/j.1365-2141.2004.05078.x
- By:
- Publication type:
- Article
Survival after relapse following tandem autotransplants in multiple myeloma patients: the University of Arkansas total therapy I experience.
- Published in:
- British Journal of Haematology, 2003, v. 123, n. 3, p. 484, doi. 10.1046/j.1365-2141.2003.04646.x
- By:
- Publication type:
- Article
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.
- Published in:
- British Journal of Haematology, 2001, v. 115, n. 3, p. 569, doi. 10.1046/j.1365-2141.2001.03155.x
- By:
- Publication type:
- Article
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab.
- Published in:
- EJHaem, 2024, v. 5, n. 4, p. 789, doi. 10.1002/jha2.971
- By:
- Publication type:
- Article
B‐cell maturation antigen‐based therapies post‐talquetamab in relapsed or refractory multiple myeloma.
- Published in:
- EJHaem, 2024, v. 5, n. 3, p. 554, doi. 10.1002/jha2.896
- By:
- Publication type:
- Article
Variability of definition of high‐risk multiple myeloma across phase III clinical trials.
- Published in:
- EJHaem, 2023, v. 4, n. 2, p. 454, doi. 10.1002/jha2.675
- By:
- Publication type:
- Article